

**GJE**

14 September 2007

European Patent Office  
Erhardtstraße 27  
80469 München  
Germany

Dear Sirs

European Patent Application No. 05706393.5  
Lorus Therapeutics Inc  
Our Ref: LAS01886EP

---

Please note our reference for this case is as above. I would be grateful if you would update the European Patent Register accordingly.

Yours faithfully  
GILL JENNINGS & EVERY LLP



Elizabeth Swan

LAS/EMS/js

EPO - Munich  
79

17 Sep. 2007

**Gill Jennings & Every LLP**

European Patent Attorneys  
European Trade Mark Attorneys

---

Broadgate House  
7 Eldon Street  
London  
EC2M 7LH

Tel: +44 (0)20 7377 1377  
Fax: +44 (0)20 7377 1310

[www.gje.co.uk](http://www.gje.co.uk)

---

**Partners:**

M J Brunner  
R E Perry  
R E Skone James  
R A Blum  
H M M Jones  
P W Harris  
C J Hucker  
S Haley  
L A Samuels  
P J Finnie  
A L MacQuarrie  
J W G Jappy  
M Lord  
A J M Smea

**Associates:**

A L P Clarke  
L C Stewart  
R G Price  
D L C Wraige  
G J Crofts  
C G Dare  
H J Scott  
E M Flexer  
B Swabe  
B Jonson  
J G Sim

Partnership Secretary: S J Pack

**Accounts:**

General Office:	A J Shafkou
Human Resources:	J M Devaney
IT Systems:	C S Tanner
Patent Formalities:	G G Amabilino
Records - Patents:	A A Heathcote
Records - Trade Marks:	G M Alderman
	J H Bedding

---

Also at: Cambridge  
Munich

---

Gill Jennings & Every LLP is registered in England and Wales as a Limited Liability Partnership.  
Registered No. 0c313165  
Registered Office: Broadgate House,  
7 Eldon Street, London EC2M 7LH



European Patent Office  
80298 MUNICH  
GERMANY  
Tel.: +49 89 2399 - 0  
Fax: +49 89 2399 - 4465

Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets



Samuels, Lucy Alice  
Gill Jennings & Every LLP  
Broadgate House  
7 Eldon Street  
London EC2M 7LH  
GRANDE BRETAGNE

EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date

07.08.07

Reference	Application No./Patent No. 05706393.5 - 2406
Applicant/Proprietor Lorus Therapeutics Inc.	

### Communication

concerning the registration of amendments relating to

- ☒ a transfer (Rules 20 and 61 EPC)  
☐ entries pertaining to the applicant/the proprietor (Rule 92(1)(f) EPC)

As requested, the entries pertaining to the applicant of the above-mentioned European patent application / to the proprietor of the above-mentioned European patent have been amended to the following:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL  
PL PT RO SE SI SK TR  
Lorus Therapeutics Inc.  
2 Meridian Road  
Toronto, Ontario M9W 4Z7/CA

The registration of the changes has taken effect on 18.07.07.

In the case of a published application/a patent, the change will be recorded in the Register of European Patents and published in the European Patent Bulletin (Section I.12/II.12).

Your attention is drawn to the fact that, in the case of the registration of a transfer, any automatic debit order only ceases to be effective from the date of its express revocation (cf. point 14(c) of the Arrangements for the automatic debiting procedure, Supplement to OJ EPO 2/2002).

**Transfer Service**  
Tel.: +49 (0)89 2399 2780





17 July 2007

European Patent Office  
Erhardtstraße 27  
80469 München  
Germany

EPO - Munich  
23

19. Juli 2007

**Gill Jennings & Every LLP**

**European Patent Attorneys  
European Trade Mark Attorneys**

Broadgate House  
7 Eldon Street  
London  
EC2M 7LH

Tel: +44 (0)20 7377 1377  
Fax: +44 (0)20 7377 1310

[www.gje.co.uk](http://www.gje.co.uk)

Dear Sirs

**European Patent Application No. 05706393.5  
GeneSense Technologies Inc  
Our Ref: LAS01886EP**

---

This application has been assigned from GeneSense Technologies Inc. of 2 Meridian Road, Toronto, Ontario, M9W 4Z7 to Lorus Therapeutics Inc. of the same address. The assignment took place 10 July 2007. Please find enclosed an assignment document as evidence of this. The above identified application is shown at the bottom of page 4 of the document.

Please record the assignment on the European Patent Register. The fee for recording the assignment will be paid by separate communication.

Yours faithfully  
GILL JENNINGS & EVERY LLP

Elizabeth Flexer

Enc

EMS/veh

---

Partners:  
M J Brunner  
R E Perry  
R E Skone James  
R A Blum  
H M M Jones  
P W Harris  
C J Hucker  
S Haley  
L A Samuels  
P J Finnie  
A L MacQuarrie  
J W G Jappy  
M Lord  
A J M Smee

Associates:  
A L P Clarke  
L C Stewart  
R G Price  
D L C Wraige  
G J Crofts  
C G Dare  
H J Scott  
E M Flexer  
B Swabe  
B Jonson  
J G Sim

Partnership Secretary: S J Pack

Accounts:	A J Shiafku
General Office:	J M Devaney
Human Resources:	C S Tanner
IT Systems:	G G Amabilino
Patent Formalities:	A A Heathcote
Records - Patents:	G M Alderman
Records - Trade Marks:	J H Bedding

Also at: Cambridge  
Munich

---

Gill Jennings & Every LLP is registered in England and Wales as a Limited Liability Partnership.  
Registered No. 0c313165  
Registered Office: Broadgate House,  
7 Eldon Street, London EC2M 7LH

## ASSIGNMENT OF INVENTION

In consideration of One (\$1.00) Dollar and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, we, **GENESENSE TECHNOLOGIES INC.** (hereinafter "the Assignor"), do hereby sell, assign and transfer to **LORUS THERAPEUTICS INC.** (hereinafter "the Assignee"), all our right, title and interest throughout the world in and to (1) the inventions relating to and described and/or claimed in the patent applications and patents listed in Schedule A; (2) all improvements, including but not limited to modifications, additions, substitutions, derivatives, and deletions to said invention(s); (3) the patent applications and patents listed in Schedule A and national phase applications thereof; (4) all other applications for Letters Patent in any country throughout the world for said invention(s) and improvements, including but not limited to all divisional, continuation, continuation-in-part, renewal, reissue, and substitute applications; (5) any Letters Patent which may issue from any of said applications as exemplified in (3) and (4) above in any country throughout the world; (6) all Convention or Treaty rights derived from any of said applications, including without limitation, all rights of priority throughout the world in and to said applications; and (7) the full and complete right to file applications for Letters Patent in the name of the Assignee, or in our name at the Assignee's election, on said invention(s) and improvements in all countries throughout the world.

For said consideration, the Assignor agrees, upon the request and at the expense of the Assignee, its successors and assigns, to execute any and all divisional, continuation, continuation-in-part, reissue and substitute applications for said invention(s) and improvements, and acknowledge and agree that all rights therein shall vest in the Assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by said Assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this assignment had not been made. In addition, the Assignor will, at the request of the Assignee, execute any and all documents required by the Assignee to fully and properly vest the aforementioned rights in the Assignee.

The undersigned hereby grants to the firm of **MBM & CO.** whose full post office address is P.O. Box 809, Station B, Ottawa, Ontario, Canada, K1P 5P9, the power to insert on this assignment any further information and/or correct any clerical error in the information pertaining to the referenced applications and patents, which may be necessary or desirable in order to comply with the patent legislation for recordation of this document.

GENESENSE Assignment of Invention

**FOR THE ASSIGNOR:**

SIGNED at Toronto, Ontario, Canada, this 10<sup>TH</sup> day of JULY, 2007.

Signature: Alice - g

Name: AIPING YOUNG

Title: PRESIDENT & CEO

**GENESENSE TECHNOLOGIES INC.**

2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada

I was personally present and did see AIPING YOUNG duly sign and execute the above assignment.

[Signature]

(Signature of witness)

VANESSA GRANT

(Name of witness)

**FOR THE ASSIGNEE:**

SIGNED at Toronto, Ontario, Canada, this 10<sup>TH</sup> day of JULY, 2007.

Signature: Alice - g

Name: AIPING YOUNG

Title: PRESIDENT & CEO

**LORUS THERAPEUTICS INC.**

2 Meridian Road, Toronto, Ontario M9W 4Z7, Canada

I was personally present and did see AIPING YOUNG duly sign and execute the above assignment.

[Signature]

(Signature of witness)

VANESSA GRANT

(Name of witness)

**Schedule A****ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF  
RIBONUCLEOTIDE REDUCTASE  
(GTI-2501)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
AUSTRALIA	2/9/2000	25292/00	780455
CANADA	2/9/2000	2,385,487	
EUROPE (Germany, Spain, France, Italy, Great Britain)	2/9/2000	903458.2	1153128
ISRAEL	2/9/2000	144727	
JAPAN	2/9/2000	2000-598631	
MEXICO	2/9/2000	2001/008137	
NEW ZEALAND	2/9/2000	514090	514090
UNITED STATES	2/11/1999	09/249,730	6,121,000
ARGENTINA	2/11/2000	P000100813	

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R1 AND  
USES THEREOF IN THE TREATMENT OF CANCER  
(GTI-2501 in combination with chemotherapy)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
CANADA	5/21/2004	2,526,393
EUROPE	5/21/2004	04734192.0
UNITED STATES	5/21/2004	10/567,853

**ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST RIBONUCLEOTIDE REDUCTASE  
(GTI-2040)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
UNITED STATES	8/1/1997	08/904,901	5,998,383

**GENESENSE Assignment of Invention**

**ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS  
OF RIBONUCLEOTIDE REDUCTASE  
(GT1-2040)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>	<b>Patent #</b>
AUSTRALIA	8/1/1997	38175/97	738592
CANADA	8/1/1997	2,262,776	2,262,776
CHINA	8/1/1997	97198163.9	97198163.9
EUROPE (Germany, Spain, France, Italy, Great Britain)	8/1/1997	97932590.7	917569
ISRAEL	8/1/1997	128124	
JAPAN	8/1/1997	10-507410	
NEW ZEALAND	8/1/1997	333802	333802
SINGAPORE	8/1/1997	8900413-7	81308
UNITED STATES	5/29/2003	10/447,138	

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R1 AND  
USES THEREOF IN THE TREATMENT OF CANCER  
(GT1-2040 in combination with chemotherapy)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
AUSTRALIA	2/10/2004	2004209579
CANADA	2/10/2004	2,535,850
EUROPE	2/10/2004	4709557.5
JAPAN	2/10/2004	2008-501413
UNITED STATES	2/10/2004	10/545,152

**ANTISENSE OLIGONUCLEOTIDES DIRECTED TO RIBONUCLEOTIDE REDUCTASE R2  
AND USES THEREOF IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER  
(GT1-2040 in combination with cytokines)**

<b>Country</b>	<b>Filed</b>	<b>Serial #</b>
AUSTRALIA	1/12/2005	2005203822
CANADA	1/12/2005	2,553,211
EUROPE	1/12/2005	5708393.5
JAPAN	1/12/2005	2008-548057
UNITED STATES	1/12/2005	10/585,772

**GENESENSE Assignment of Invention**

**OLIGONUCLEOTIDES FROM THE UNTRANSLATED REGIONS OF RIBONUCLEOTIDE REDUCTASE AND THEIR USE TO MODULATE CELL GROWTH (U-sense)**

Country	Filed	Serial #	Patent #
CANADA	6/30/1997	2,259,123	2,259,123

**INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE REDUCTASE UTR (U-sense)**

Country	Filed	Serial #
UNITED STATES	5/10/2002	09/214,388
UNITED STATES	8/8/2005	11/188,351

**ANTITUMOR ANTISENSE SEQUENCES DIRECTED AGAINST R1 AND R2 COMPONENTS OF RIBONUCLEOTIDE REDUCTASE (R1 antisense excluding GT1-2501)**

Country	Filed	Serial #	Patent #
UNITED STATES	2/11/1999	09/249,247	6,593,305

**SUPPRESSION OF MALIGNANCY UTILIZING RIBONUCLEOTIDE REDUCTASE R1 (R1 Gene Therapy)**

Country	Filed	Serial #	Patent #
AUSTRALIA	3/18/1998	64922/98	742176
CANADA	3/18/1998	2,301,874	
EUROPE (Germany, Spain, France, Italy, Great Britain)	3/18/1998	98910553.1	971731
HONG KONG	3/18/1998	104079.6	1024640
JAPAN	3/18/1998	10-539987	
SINGAPORE	3/18/1998	9904590-8	68137
UNITED STATES	3/18/1998	09/155,248	6,472,376
UNITED STATES	8/20/2002	10/223,655	

**ANTISENSE OLIGONUCLEOTIDE SEQUENCES AS INHIBITORS OF MICROORGANISMS**

Country	Filed	Serial #	Patent #
CANADA	7/10/1998	2,294,306	2,294,305
UNITED STATES	7/8/1998	09/112,580	6,610,539



**NEUROPILIN ANTISENSE OLIGONUCLEOTIDE SEQUENCES AND METHODS OF  
USING SAME TO MODULATE CELL GROWTH  
(GTI-3611)**

Country	Filed	Serial #	Patent #
AUSTRALIA	4/23/1999	34022/99	747639
MEXICO	4/23/1999	10277	
UNITED STATES	3/19/2002	09/288,264	7,087,580

**OLIGONUCLEOTIDE SEQUENCES COMPLEMENTARY TO THIOREDOXIN OR THIOREDOXIN  
REDUCTASE GENES AND METHODS OF USING SAME TO MODULATE CELL GROWTH  
(GTI-2601; GTI-3008)**

Country	Filed	Serial #	Patent #
AUSTRALIA	1/29/1999	22612/99	760396
CHINA	1/29/1999	99802489.9	
MEXICO	1/29/1999	7455	
UNITED STATES	1/29/1999	09/601,144	6,568,514

**INSULIN-LIKE GROWTH FACTOR II ANTISENSE OLIGONUCLEOTIDE SEQUENCES  
AND METHODS OF USING SAME TO MODULATE CELL GROWTH  
(GTI-4006)**

Country	Filed	Serial #	Patent #
AUSTRALIA	4/23/1999	34021/99	749802
CANADA	4/23/1999	2,328,825	
MEXICO	4/23/1999	10215	
UNITED STATES	4/22/1999	09/295,593	6,417,169

**SMALL INTERFERING RNA MOLECULES AGAINST RIBONUCLEOTIDE REDUCTASE  
AND USES THEREOF  
(siRNA)**

Country	Filed	Serial #
CANADA	8/18/2005	2,577,038
EUROPE	8/18/2005	5774823.8
UNITED STATES	8/18/2005	11/573,879

**PREPARATIONS OF ANTISENSE OLIGONUCLEOTIDES AGAINST THIOREDOXIN  
AND USES THEREOF  
(GTI-2601/Sumitomo collaboration)**

Country	Filed	Serial #
UNITED STATES	4/9/2007	60/910,689

18-JUL-07 11:46

FROM-GILL JENNINGS &amp; EVERY LLP

+44 20 7377 1310

T-185 P.001/001 F-770

# **Payment of fees and costs**

## **Zur Kasse**

Treasury and Accounts  
D - 80298 Munchen  
Fax: (+49-89) 2399-2528  
(only for matters relating  
to accounts)


Please complete in typescript only

Name of payer		Payer's reference	
01	Gill Jennings & Every LLP	LAS01886EP	20/07/07
Address		Made of payment	Bank/Giro Office
Broadgate House		<input type="checkbox"/> Bank/Giro transfer	
7 Eldon Street		<input type="checkbox"/> Enclosed Cheque No.	
02	London EC2M 7LH UK.	<input checked="" type="checkbox"/> Debit from deposit account with the EPO is requested	Deposit account No. 2805.0014

Patent application / Patent No. (please use a separate form for each application)

03	EP	05706393.5	PCT	PCT/CA05/00040	03
	Code		Currency	Amount	
04	001	Filing fee			
05	002	Search fee			
06	005	Designation fee(s)			
07	015	Claims fee(s) (Rule 31 (1) EPC)			
08	055	Additional copy			
09	006	Examination fee			
10	007	Fee for grant including fee for printing (up to 35 pages)			
11	008	Additional fee for printing (more than 35 pages)			
12	033	Renewal fee for the 3rd year			
13	034	Renewal fee for the 4th year			
14	035	Renewal fee for the 5th year			
15	022	Registration of transfer	EUR	80.00	
16					
17					
18					
19					
20					
21					
22					
Total			EUR	80.00	

Signature



Place, Date

London

18 JUL 2007



11 April 2007

European Patent Office  
Erhardtstraße 27  
80469 München  
Germany

Dear Sirs

European Patent Application No. 05706393.5  
GeneSense Technologies Inc  
Our Ref: LAS01886EP

---

In response to the communication dated 23 March 2007, a sequence listing on the prescribed data carrier is filed herewith. The information recorded on the data carrier is identical to the written sequence listing.

Yours faithfully  
GILL JENNINGS & EVERY LLP

Elizabeth Flexer

JWJ/GJT/lmw

EPO - Munich  
29

13 April 2007

**Gill Jennings & Every LLP**

European Patent Attorneys  
European Trade Mark Attorneys

---

Broadgate House  
7 Eldon Street  
London  
EC2M 7LH

Tel: +44 (0)20 7377 1377  
Fax: +44 (0)20 7377 1310

[www.gje.co.uk](http://www.gje.co.uk)

---

Partners:  
M J Brunner  
R E Perry  
R E Skone James  
R A Blum  
H M M Jones  
P W Harris  
C J Hucker  
S Haley  
L A Samuels  
P J Finnie  
A L MacQuarrie  
J W G Jappy  
M Lord  
A J M Smee

Associates:  
L C Stewart  
R G Price  
D L C Wraige  
G J Crofts  
C G Dare  
H J Scott  
E M Flexer  
B Swabe  
B Jonson  
J G Sim

Partnership Secretary: S J Pack

Accounts:	A J Shiafkou
General Office:	J M Devaney
Human Resources:	C S Tanner
IT Systems:	G G Amabilino
Patent Formalities:	A A Heathcote
Records - Patents:	G M Alderman
Records - Trade Marks:	J H Bedding

---

Also at: Cambridge  
Munich

---

Gill Jennings & Every LLP is registered in England and Wales as a Limited Liability Partnership.  
Registered No. 0c313165  
Registered Office: Broadgate House,  
7 Eldon Street, London EC2M 7LH

# Filing Office Munich

File Number : 05706393.5

EPO - Munich  
29

Date of Receipt : 13. April 2007

SEQL disc (EP)

EPO - Munich  
29

13. April 2007

Sent on :

To : Karine Martin  
(Munich - Room 2610)



European Patent Office  
80298 MUNICH  
GERMANY  
Tel.: +49 89 2399 - 0  
Fax: +49 89 2399 - 4465

Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Samuels, Lucy Alice  
Gill Jennings & Every LLP  
Broadgate House  
7 Eldon Street  
London EC2M 7LH  
GRANDE BRETAGNE



EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date

23-03-2007

Reference	Application No./Patent No. 05706393.5 - 2406 PCT/CA2005000040
Applicant/Proprietor GeneSense Technologies Inc.	

**Formalities examination - Invitation to remedy deficiencies  
(Art. 91(2), R. 27a, 41(1) and 111(3) EPC)**

The examination by the Receiving Section prescribed in Article 91(1)(b) and (d) EPC has revealed that the invention as disclosed in the above-mentioned European patent application contains nucleotides and/or amino acid sequences for which:

- ☐ no sequence listing has been submitted (R. 27a(1), 111(3) EPC);
- ☐ the sequence listing submitted does not comply with the rules laid down by the President of the European Patent Office in accordance with Rule 27a(1), Rule 111(3) EPC (cf. Decision of the President of the EPO dated 2 October 1998, published in Supplement No. 2 to Official Journal No. 11/1998) since
  - ☐ one or more of the mandatory items is (are) not indicated in the sequence listing;
  - ☐ not all the sequences disclosed in the application are included in the sequence listing;
  - ☐ the sequence listing is not represented in accordance with WIPO standard ST.25;
- ☒ the sequence listing was not submitted on the prescribed data carrier (R. 27a(2), 111(3) EPC and the above-mentioned decision of the President);
- ☐ the statement that the information recorded on the data carrier is identical to the written sequence listing is missing (R. 27a(2) EPC);
- ☐ the data carrier is damaged and cannot be used;



☐ Whereas the sequence listing was filed subsequently to the filing date, it is not accompanied by a statement that it does not include matter which goes beyond the content of the application as filed (R. 27a(3) EPC);

☒ see Annex

You are requested to remedy the deficiency within a

☒ period of **two months**

☐ non-extendable period of **one month**

after notification of this communication (R. 41(1) EPC and Art. 3 of the decision of the President).

If the specified deficiency is not remedied in due time, the European patent application will be refused (Art. 91(3) EPC).

We also draw your attention to the fact that any sequence listing submitted in response to this communication must be accompanied by a statement that it does not include matter which goes beyond the content of the application as filed and that the information recorded on the data carrier is identical to the written sequence listing.

Receiving Section



**Registered letter**



Sequence Listing Department  
P.B. 5818 - Patentlaan 2  
2280 HV Rijswijk (ZH)  
tel. +31 70 340 27 58 (direct)  
fax +31 70 340 39 92 (direct)

Europäisches  
Patentamt

Eingangsstelle

European  
Patent Office

Receiving Section

Office Européen  
des Brevets

Section de dépôt

## **ANNEX**

**N.B.: The computer-readable form of the Sequence Listing was not furnished to the EPO.**

**The EPO hereby invites the applicant to submit a sequence listing, in computer-readable form, accompanied by the appropriate statement (Rule 27a(2) EPC).**

We strongly recommend the applicant to use the **PatentIn** software to submit the sequence listing. For further details on how to obtain this software, see the remark below.

For further questions relating to the technical aspects of filing a sequence listing, please do not hesitate to contact Mr. Stéphane Nauche (tel.+31 70 340 2758). To avoid any possible processing delay, please send sequence listing on paper and in computer-readable form (preferably in ASCII format) to the above address.

### **REMARK:**

The latest version of PatentIn is available on our EPO website with following InterNet address:

[www.european-patent-office.org/filingsoft/strand](http://www.european-patent-office.org/filingsoft/strand)

Download is performed from that site, by following the download procedure. Please read carefully the information provided on that site.

The downloaded INSTALL.EXE file can be used for the installation of the new version from PatentIn. Once installed, W\_UPATIN.EXE is the file to start PatentIn.

Tips with practical details about the use of PatentIn are available on that site as well.

If problems arise with the download of the PatentIn Software, a CD-ROM copy can be obtained through our Helpdesk via e-mail:

[epoline@epo.org](mailto:epoline@epo.org)

For the download of the WIPO Standard ST.25, please activate the appropriate 'PDF' icon in the WIPO ST.25 paragraph. The Supplement No.2 to Official Journal No. 11/1998 can also be directly accessed at the following address:

[www.european-patent-office.org/epo/pubs/oj98/11\\_98/11\\_s2\\_e.pdf](http://www.european-patent-office.org/epo/pubs/oj98/11_98/11_s2_e.pdf)



P.B.5818 - Patentlaan 2  
2280 HV Rijswijk (ZH)  
☎ (070) 3 40 20 40  
FAX (070) 3 40 30 16

Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Generaldirektion 1

Directorate General 1

Direction générale 1

Samuels, Lucy Alice  
Gill Jennings & Every LLP  
Broadgate House  
7 Eldon Street  
London EC2M 7LH  
GRANDE BRETAGNE



EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date

05.10.06

Reference	Application No./Patent No. 05706393.5 - 2403 PCT/CA2005000040
Applicant/Proprietor GeneSense Technologies Inc.	

#### Notification of European publication number and information on the application of Article 67(3) EPC

The provisional protection under Article 67(1) and (2) EPC in the individual contracting states becomes effective only when the conditions referred to in Article 67(3) EPC have been fulfilled (for further details, see information brochure of the European Patent Office "National Law relating to the EPC" and additional information in the Official Journal of the European Patent Office).

Pursuant to Article 158(1) EPC the publication under Article 21 PCT of an international application for which the European Patent Office is a designated Office takes the place of the publication of a European patent application.

The bibliographic data of the above-mentioned Euro-PCT application will be published on 02.11.06 in Section I.1 of the European Patent Bulletin. The European publication number is 1715896.

In all future communications to the European Patent Office, please quote the application number plus Directorate number.

Receiving Section







P.B.5818 - Patentlaan 2  
2280 HV Rijswijk (ZH)  
☎ (070) 3 40 20 40  
FAX (070) 3 40 30 16

Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Generaldirektion 1

Directorate General 1

Direction générale 1

Samuels, Lucy Alice  
Gill Jennings & Every LLP  
Broadgate House  
7 Eldon Street  
London EC2M 7LH  
GRANDE BRETAGNE



EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date 01-09-2006

Reference	Application No./Patent No. 05706393.5 - 2403 PCT/CA2005000040
Applicant/Proprietor GeneSense Technologies Inc.	

#### Communication pursuant to Rules 109 and 110 EPC

##### (1) Amendment of application documents, especially the claims (R. 109 EPC)

The above mentioned international (Euro-PCT) application has entered the European phase, or can do so, once the necessary conditions are fulfilled.

Under Articles 28, 41 PCT, Rules 52, 78 PCT and Rule 86(2) to (4) EPC, the applicant may amend the application documents after receiving the international search report.

**Whether or not he has already done so, he now has a further opportunity to file amended claims or other application documents within a non-extendable time limit of one month after notification of the present communication (R. 109 EPC).**

The claims applicable on expiry of the above time limit, i.e. those filed on entry into the European phase or in response to the present communication, will form the basis for the calculation of any claims fee to be paid (see page 2) and for any supplementary search to be carried out under Article 157(2) EPC (R. 109 EPC).

**(2) Claims fees under Rule 110 EPC**

If the application documents on which the European grant procedure is to be based comprise more than ten claims, a claims fee shall be payable for the eleventh and each subsequent claim within the period provided for in Rule 107(1) EPC.

- ☒ Based on the application documents currently on file, all necessary claims fees have already been paid (or the documents do not comprise more than 10 claims).
- ☐ All necessary fees will be/have been debited automatically according to the automatic debit order.
- ☐ The claims fee due for the claims ..... to ..... were not paid within the above-mentioned period.

Any non-paid claims fee, either based on the current set of claims or on any amended claims to be filed pursuant to Rule 109 EPC (see page 1), may still be validly paid within a non-extendable period of grace of **one month** after notification of this communication.

If a payment is made for only some of the claims, it must be indicated for which claims it is intended. If a claims fee is not paid in due time, the claim concerned is deemed to be abandoned (R. 110(4) EPC).

If claims fees have already been paid, but on expiry of the above-mentioned time limit there is a new set of claims containing fewer fee-incurring claims than previously, the claims fees in excess of those due under Rule 110(2), 2nd sentence, EPC will be refunded (R. 110(3) EPC).

You are reminded that any supplementary search under Article 157(2) EPC will relate only to the last set of claims applicable on expiry of the above time limit AND will be confined to those fee-incurring claims for which fees have been paid in due time.

**The fee for the eleventh and each subsequent claim is EUR 45,00.**

Receiving Section





An das Europäische Patentamt

To the European Patent Office

A l'Office européen des brevets

1

EPO - Munich  
67

09. Aug. 2006

**Eintritt in die  
europäische Phase  
(EPA als Bestimmungsamt  
oder ausgewähltes Amt)****Entry into the  
European phase  
(EPO as designated or  
elected Office)****Entrée dans la  
phase européenne  
(l'OEB agissant en qualité  
d'office désigné ou élu)**

Europäische Anmeldenummer oder, falls nicht bekannt, PCT-Aktenzeichen oder PCT-Veröffentlichungsnummer	European application number, or, if not known, PCT application or publication number	Numéro de dépôt de la demande de brevet européen ou, à défaut, numéro de dépôt PCT ou de publication PCT
05706393.5 (PCT/CA 05/00040)		
Zeichen des Anmelders oder Vertreters (max. 15 Positionen)	Applicant's or representative's reference (max. 15 spaces)	Référence du demandeur ou du mandataire (15 caractères ou espaces au maximum)
LAS01886EP		
<input checked="" type="checkbox"/> 1. <b>Anmelder</b> Die Angaben über den (die) Anmelder sind in der internationalen Veröffentlichung enthalten oder vom Internationalen Büro nach der internationalen Veröffentlichung vermerkt worden.	1. <b>Applicant</b> Indications concerning the applicant(s) are contained in the international publication or recorded by the International Bureau after the international publication.	1. <b>Demandeur</b> Les indications concernant le(s) demandeur(s) figurent dans la publication internationale ou ont été enregistrées par le Bureau international après la publication internationale.
<input type="checkbox"/> Änderungen, die das Internationale Büro noch nicht vermerkt hat, sind auf einem Zusatzblatt angegeben. <b>Zustellanschrift</b> (siehe Merkblatt II, 1)	Changes which have not yet been recorded by the International Bureau are set out on an additional sheet. <b>Address for correspondence</b> (see Notes II, 1)	Les changements qui n'ont pas encore été enregistrés par le Bureau international sont indiqués sur une feuille additionnelle. <b>Adresse pour la correspondance</b> (voir notice II, 1)
2. <b>Vertreter</b>  <b>Name</b> (Nur einen Vertreter angeben, der in das europäische Patentregister eingetragen und an den zugestellt wird)  <b>Geschäftsanschrift</b>  <b>Telefon</b>  <b>Telefax</b> <b>Telex</b>	2. <b>Representative</b>  <b>Name</b> (Name only one representative who will be listed in the Register of European Patents and to whom notification will be made) <b>SAMUELS, Lucy Alice</b> <b>Address of place of business</b> Gill Jennings & Every LLP Broadgate House 7 Eldon Street London EC2M 7LH <b>Telephone</b> 020 7377-1377 <b>Fax</b> <b>Telex</b> 020 7377-1310  Additional representative(s) on additional sheet	2. <b>Mandataire</b>  <b>Nom</b> (N'indiquer qu'un seul mandataire, qui sera inscrit au Registre européen des brevets et auquel signification sera faite)  <b>Adresse professionnelle</b>  <b>Téléphone</b>  <b>Téléfax</b> <b>Télex</b>  Autre(s) mandataire(s) sur une feuille additionnelle
<input type="checkbox"/> Weitere(r) Vertreter auf Zusatzblatt		
3. <b>Vollmacht</b>  <input type="checkbox"/> Einzelvollmacht ist beigefügt. <input type="checkbox"/> Allgemeine Vollmacht ist registriert unter Nummer:  <input type="checkbox"/> Allgemeine Vollmacht ist eingereicht, aber noch nicht registriert. <input type="checkbox"/> Die beim EPA als PCT-Anmeldeamt eingereichte Vollmacht schließt ausdrücklich die europäische Phase ein.	3. <b>Authorisation</b>  Individual authorisation is attached.  General authorisation has been registered under No:  A general authorisation has been filed, but not yet registered.  The authorisation filed with the EPO as PCT receiving Office expressly includes the European phase.	3. <b>Pouvoir</b>  Un pouvoir spécial est joint.  Un pouvoir général a été enregistré sous le n°:  Un pouvoir général a été déposé, mais n'est pas encore enregistré.  Le pouvoir général déposé à l'OEB agissant en qualité d'office récepteur au titre du PCT s'applique expressément à la phase européenne.


<p><input checked="" type="checkbox"/> <b>4. Prüfungsantrag</b> Hiermit wird die Prüfung der Anmeldung gemäß Art. 94 EPU beantragt. Die Prüfungsgebühr wird (wurde) entrichtet.</p> <p>Prüfungsantrag in einer zugelassenen Nichtamtssprache (siehe Merkblatt III, 5.2) :</p>	<p><b>4. Request for examination</b> Examination of the application under Art. 94 EPC is hereby requested. The examination fee is being (has been, will be) paid.</p> <p>Request for examination in an admissible non-EPO language (see Notes III, 5.2) :</p>	<p><b>4. Requête en examen</b> Il est demandé que soit examinée la demande de brevet conformément à l'art. 94 CBE. Il est (a été, sera) procédé au paiement de la taxe d'examen.</p> <p>Requête en examen dans une langue non officielle autorisée (voir notice III, 5.2) :</p>
<p><input checked="" type="checkbox"/> <b>5. Abschriften</b> Zusätzliche Abschrift(en) der im ergänzenden europäischen Recherchenbericht angeführten Schriftstücke wird (werden) beantragt.</p> <p>Anzahl der <b>zusätzlichen</b> Sätze von Abschriften</p>	<p><b>5. Copies</b> Additional copy (copies) of the documents cited in the supplementary European search report is (are) requested.</p> <p>Number of <b>additional</b> sets of copies</p>	<p><b>5. Copies</b> Prière de fournir une ou plusieurs copies supplémentaires des documents cités dans le rapport complémentaire de recherche européenne.</p> <p>Nombre de jeux <b>supplémentaires</b> de copies</p>
<p><b>6. Für das Verfahren vor dem EPA bestimmte Unterlagen</b></p> <p>6.1 Dem Verfahren vor dem EPA als <b>Bestimmungsamt</b> (PCT I) sind folgende Unterlagen zugrunde zu legen:</p> <p><input checked="" type="checkbox"/> die vom Internationalen Büro veröffentlichten <b>Anmeldungsunterlagen</b> (mit allen Ansprüchen, Beschreibung und Zeichnungen), gegebenenfalls mit den geänderten Ansprüchen nach Art. 19 PCT</p> <p><input type="checkbox"/> soweit sie nicht ersetzt werden durch die beigefügten <b>Änderungen</b>.</p> <p><i>Falls nötig, sind Klarstellungen auf einem Zusatzblatt einzureichen!</i></p> <p>6.2 Dem Verfahren vor dem EPA als <b>ausgewähltem Amt</b> (PCT II) sind folgende Unterlagen zugrunde zu legen:</p> <p><input checked="" type="checkbox"/> die dem Internationalen vorläufigen Prüfungsbericht zugrunde gelegten <b>Unterlagen</b>, einschließlich seiner eventuellen <b>Anlagen</b> (Solche Anlagen müssen immer beigefügt werden)</p> <p><input checked="" type="checkbox"/> soweit sie nicht ersetzt werden durch die beigefügten <b>Änderungen</b>.</p> <p><i>Falls nötig, sind Klarstellungen auf einem Zusatzblatt einzureichen!</i></p> <p><input checked="" type="checkbox"/> Sind dem EPA als mit der internationalen vorläufigen Prüfung beauftragten Behörde <b>Versuchsberichte</b> zugegangen, dürfen diese dem Verfahren vor dem EPA zugrunde gelegt werden.</p>	<p><b>6. Documents intended for proceedings before the EPO</b></p> <p>6.1 Proceedings before the EPO as <b>designated Office</b> (PCT I) are to be based on the following documents:</p> <p>the <b>application documents published</b> by the International Bureau (with all claims, description and drawings), where applicable with amended claims under Art. 19 PCT</p> <p>unless replaced by the <b>amendments</b> enclosed.</p> <p><i>Where necessary, clarifications must be submitted on a separate sheet!</i></p> <p>6.2 Proceedings before the EPO as <b>elected Office</b> (PCT II) are to be based on the following documents:</p> <p>the <b>documents on which the international preliminary examination report is based</b>, including its possible <b>annexes</b> (Such annexes must always be filed)</p> <p>unless replaced by the <b>amendments</b> enclosed.</p> <p><i>Where necessary, clarifications must be submitted on a separate sheet!</i></p> <p>If the EPO as International Preliminary Examining Authority has received <b>test reports</b>, these may be used as the basis of proceedings before the EPO.</p>	<p><b>6. Pièces destinées à la procédure devant l'OEB</b></p> <p>6.1 La procédure devant l'OEB agissant en qualité d'<b>office désigné</b> (PCT I) doit se fonder sur les pièces suivantes :</p> <p>les <b>pièces de la demande publiée</b> par le Bureau international (avec toutes les revendications, la description et les dessins), éventuellement avec les revendications modifiées conformément à l'article 19 du PCT</p> <p>dans la mesure où elles ne sont pas remplacées par les <b>modifications</b> jointes.</p> <p><i>Le cas échéant, des explications doivent être jointes sur une feuille additionnelle!</i></p> <p>6.2 La procédure devant l'OEB agissant en qualité d'<b>office élu</b> (PCT II) doit se fonder sur les pièces suivantes :</p> <p>les <b>pièces sur lesquelles se fonde le rapport d'examen préliminaire international</b>, y compris ses <b>annexes</b> éventuelles (De telles annexes sont toujours à joindre)</p> <p>dans la mesure où elles ne sont pas remplacées par les <b>modifications</b> jointes.</p> <p><i>Le cas échéant, des explications doivent être jointes sur une feuille additionnelle!</i></p> <p>Si l'OEB, agissant en qualité d'administration chargée de l'examen préliminaire international, a reçu des <b>rapports d'essais</b>, ceux-ci peuvent constituer la base de la procédure devant l'OEB.</p>

<p><b>7. Übersetzungen</b> Beigefügt sind die nachfolgend angekreuzten Übersetzungen in einer der Amtssprachen des EPA (Deutsch, Englisch, Französisch):</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Im Verfahren vor dem EPA als <b>Bestimmungsamt oder ausgewähltem Amt</b> (PCT I + II):</li> <li><input type="checkbox"/> Übersetzung der <b>ursprünglich eingereichten internationalen Anmeldung</b> (Beschreibung, Ansprüche, etwaige Textbestandteile in den Zeichnungen), der veröffentlichten Zusammenfassung, und etwaiger Angaben über biologisches Material nach Regel 13<sup>ter</sup>.3 und 13<sup>ter</sup>.4 PCT</li> <li><input type="checkbox"/> Übersetzung der <b>prioritätsbegründenden Anmeldung(en)</b></li> <li><input type="checkbox"/> Es wird hiermit erklärt, daß die internationale Anmeldung in ihrer ursprünglich eingereichten Fassung eine vollständige Übersetzung der früheren Anmeldung ist (Regel 38(5) EPU)</li> <li><input type="checkbox"/> <b>Zusätzlich im Verfahren vor dem EPA als Bestimmungsamt</b> (PCT I):</li> <li><input type="checkbox"/> Übersetzung der nach Art. 19 PCT <b>geänderten Ansprüche</b> nebst Erklärung, falls diese dem Verfahren vor dem EPA zugrunde gelegt werden sollen (siehe Feld 6)</li> <li><input type="checkbox"/> <b>Zusätzlich im Verfahren vor dem EPA als ausgewähltem Amt</b> (PCT II):</li> <li><input type="checkbox"/> Übersetzung der <b>Anlagen zum internationalen vorläufigen Prüfungsbericht</b></li> </ul>	<p><b>7. Translations</b> Translations in one of the official languages of the EPO (English, French, German) are enclosed as crossed below:</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> In proceedings before the EPO as <b>designated or elected Office</b> (PCT I + II):</li> <li>Translation of the <b>international application</b> (description, claims, any text in the drawings) as <b>originally filed</b>, of the abstract as published and of any indication under Rule 13<sup>ter</sup>.3 and 13<sup>ter</sup>.4 PCT regarding biological material</li> <li>Translation of the <b>priority application(s)</b></li> <li>It is hereby declared that the international application as originally filed is a complete translation of the previous application (Rule 38(5) EPC)</li> <li><input type="checkbox"/> In addition, in proceedings before the EPO as <b>designated Office</b> (PCT I):</li> <li>Translation of <b>amended claims</b> and any statement under Art. 19 PCT, if the claims as amended are to form the basis for the proceedings before the EPO (see Section 6)</li> <li><input type="checkbox"/> In addition, in proceedings before the EPO as <b>elected Office</b> (PCT II):</li> <li>Translation of any <b>annexes to the international preliminary examination report</b></li> </ul>	<p><b>7. Traductions</b> Vous trouverez, ci-joint, les traductions cochées ci-après dans l'une des langues officielles de l'OEB (allemand, anglais, français) :</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Dans la procédure devant l'OEB agissant en qualité d'<b>office désigné ou élu</b> (PCT I + II):</li> <li>Traduction de la <b>demande internationale telle que déposée initialement</b> (description, revendications, textes figurant éventuellement dans les dessins), de l'abrégé publié, et de toutes indications visées aux règles 13<sup>ter</sup>.3 et 13<sup>ter</sup>.4 du PCT concernant le matériel biologique</li> <li>Traduction de la (des) <b>demande(s) ouvrant le droit de priorité</b></li> <li>Il est déclaré par la présente que la demande internationale telle que déposée initialement est une traduction intégrale de la demande antérieure (règle 38(5) CBE)</li> <li><input type="checkbox"/> De plus, dans la procédure devant l'OEB agissant en qualité d'<b>office désigné</b> (PCT I) :</li> <li>Traduction des <b>revendications modifiées</b> et de la déclaration faite conformément à l'article 19 du PCT, si la procédure devant l'OEB doit être fondée sur les revendications modifiées (voir la rubrique 6)</li> <li><input type="checkbox"/> De plus, dans la procédure devant l'OEB agissant en qualité d'<b>office élu</b> (PCT II) :</li> <li>Traduction des <b>annexes du rapport d'examen préliminaire international</b></li> </ul>
<p><input type="checkbox"/> <b>8. Biologisches Material</b> Die Erfindung bezieht sich auf bzw. verwendet biologisches Material, das nach Regel 28 EPU hinterlegt worden ist.</p> <p><input type="checkbox"/> Die Angaben nach Regel 28(1)c) EPU (falls noch nicht bekannt, die Hinterlegungsstelle und das (die) Bezugszeichen (Nummer, Symbole usw.) des Hinterlegers) sind in der internationalen Veröffentlichung oder in der gemäß Feld 7 eingereichten Übersetzung enthalten auf:</p> <p>Seite(n) / Zeile(n)</p> <p>Die <b>Empfangsbescheinigung(en)</b> der Hinterlegungsstelle</p> <p><input type="checkbox"/> ist (sind) beigefügt</p> <p><input type="checkbox"/> wird (werden) nachgereicht</p> <p><input type="checkbox"/> Verzicht auf die Verpflichtung des Antragstellers nach Regel 28(3) EPU auf gesondertem Schriftstück</p>	<p><input type="checkbox"/> <b>8. Biological material</b> The invention relates to and/or uses biological material deposited under Rule 28 EPC.</p> <p>The particulars referred to in <b>Rule 28(1)(c) EPC</b> (if not yet known, the depository institution and the identification reference(s) [number, symbols etc.] of the depositor) are given in the international publication or in the translation submitted under Section 7 on:</p> <p>page(s) / line(s)</p> <p>The <b>receipt(s) of deposit</b> issued by the depository institution</p> <p>is (are) enclosed</p> <p>will be filed at a later date</p> <p>Waiver of the right to an undertaking from the requester pursuant to Rule 28(3) EPC attached.</p>	<p><input type="checkbox"/> <b>8. Matière biologique</b> L'invention concerne et/ou utilise de la matière biologique, déposée conformément à la règle 28 CBE.</p> <p>Les indications visées à la <b>règle 28(1)c) CBE</b> (si non encore connues, l'autorité de dépôt et la (les) référence(s) d'identification [numéro ou symboles etc.] du déposant) figurent dans la publication internationale ou dans une traduction produite conformément à la rubrique 7 à la / aux:</p> <p>page(s) / ligne(s)</p> <p>Le(s) <b>récépissé(s) de dépôt</b> délivré(s) par l'autorité de dépôt</p> <p>est (sont) joint(s)</p> <p>sera (seront) produit(s) ultérieurement</p> <p>Renonciation, sur document distinct, à l'engagement du requérant au titre de la règle 28(3) CBE.</p>

<p><b>9. Nucleotid- und Aminosäuresequenzen</b> Die nach Regeln 5.2 und 13<sup>ter</sup> PCT sowie Regel 111(3) EPÜ erforderlichen Unterlagen liegen dem EPA bereits vor.</p> <p><input type="checkbox"/> Das schriftliche Sequenzprotokoll wird anliegend nachgereicht.</p> <p><input checked="" type="checkbox"/> Das Sequenzprotokoll geht nicht über den Inhalt der Anmeldung in der ursprünglich eingereichten Fassung hinaus.</p> <p><input type="checkbox"/> Der vorgeschriebene Datenträger ist beigelegt.</p> <p><input type="checkbox"/> Die auf dem Datenträger gespeicherte Information stimmt mit dem schriftlichen Sequenzprotokoll überein.</p>	<p><b>9. Nucleotide and amino acid sequences</b> The items necessary in accordance with Rules 5.2 and 13<sup>ter</sup> PCT and Rule 111(3) EPC have already been furnished to the EPO.</p> <p>The written sequence listing is furnished herewith.</p> <p>The sequence listing does not include matter which goes beyond the content of the application as filed.</p> <p>The prescribed data carrier is enclosed.</p> <p>The information recorded on the data carrier is identical to the written sequence listing.</p>	<p><b>9. Séquences de nucléotides et d'acides aminés</b> Les pièces requises selon les règles 5.2 et 13<sup>ter</sup> PCT et la règle 111(3) CBE ont déjà été déposées auprès de l'OEB.</p> <p>La liste de séquences écrite est produite ci-joint.</p> <p>La liste de séquences ne contient pas d'éléments s'étendant au-delà du contenu de la demande telle qu'elle a été déposée.</p> <p>Le support de données prescrit est joint.</p> <p>L'information figurant sur le support de données est identique à celle que contient la liste de séquences écrite.</p>
<p><b>10. Benennungsgebühren</b></p> <p><input checked="" type="checkbox"/> 10.1 Es ist derzeit beabsichtigt, den siebenfachen Betrag einer Benennungsgebühr zu entrichten. Damit gelten die Benennungsgebühren für alle Vertragsstaaten des EPÜ<sup>1</sup> als entrichtet (Art. 2 Nr. 3 GebO), soweit sie in der internationalen Anmeldung bestimmt sind<sup>2</sup>.</p> <p><input type="checkbox"/> 10.2 Abweichend von der Erklärung in Nr. 10.1 ist derzeit beabsichtigt, weniger als sieben Benennungsgebühren für folgende in der internationalen Anmeldung bestimmte Vertragsstaaten des EPÜ<sup>2</sup> zu entrichten:</p> <p>(1) <input type="text"/> _____</p> <p>(2) <input type="text"/> _____</p> <p>(3) <input type="text"/> _____</p> <p>Soweit unter Nr. 10.2 Vertragsstaaten aufgeführt sind, wird beantragt, für die dort nicht aufgeführten Vertragsstaaten von der Zustellung einer Mitteilung nach Regel 108(3) EPÜ abzusehen.</p> <p><input checked="" type="checkbox"/> 10.3 Wird ein automatischer Abbuchungsauftrag erteilt (Feld 12), so wird das EPA beauftragt, bei Ablauf der Grundfrist nach Regel 107 (1)(d) EPÜ den siebenfachen Betrag einer Benennungsgebühr abzubuchen. Ist eine Erklärung nach Nr. 10.2 abgegeben worden, so sollen die Benennungsgebühren nur für die dort angegebenen Vertragsstaaten abgebucht werden, sofern dem EPA nicht bis zum Ablauf der Grundfrist ein anderslautender Auftrag zugeht.</p>	<p><b>10. Designation fees</b></p> <p>10.1 It is currently intended to pay seven times the amount of the designation fee. The designation fees for all the EPC contracting states<sup>1</sup> designated in the international application<sup>2</sup> are thereby deemed to have been paid (Art. 2 No. 3 RFees).</p> <p>10.2 The declaration in No. 10.1 does not apply. Instead, it is currently intended to pay fewer than seven designation fees for the following EPC contracting states<sup>2</sup> designated in the international application:</p> <p>(4) <input type="text"/> _____</p> <p>(5) <input type="text"/> _____</p> <p>(6) <input type="text"/> _____</p> <p>If contracting states are indicated under No. 10.2, it is requested that no communication under Rule 108(3) EPC be issued for contracting states not thus indicated.</p> <p>10.3 If an automatic debit order has been issued (Section 12), the EPO is authorised, on expiry of the basic period under Rule 107(1)(d) EPC, to debit seven times the amount of the designation fee. If states are indicated under No. 10.2, the EPO will debit designation fees only for those states, unless instructed otherwise before the basic period expires.</p>	<p><b>10. Taxes de désignation</b></p> <p>10.1 Il est actuellement envisagé de payer un montant correspondant à sept fois la taxe de désignation. Les taxes de désignation sont ainsi réputées payées pour tous les Etats contractants de la CBE<sup>1</sup> désignés dans la demande internationale<sup>2</sup> (art. 2, point 3 du RRT).</p> <p>10.2 Contrairement à ce qui est indiqué au n° 10.1, il est actuellement envisagé de payer moins de sept taxes de désignation pour les Etats contractants de la CBE<sup>2</sup> suivants désignés dans la demande internationale :</p> <p>Si des Etats contractants sont mentionnés au n° 10.2, prière de ne pas procéder à la signification d'une notification prévue par la règle 108(3) CBE pour les Etats contractants n'y étant pas mentionnés.</p> <p>10.3 Si un ordre de prélèvement automatique est donné (rubrique 12), il est demandé à l'OEB de prélever, à l'expiration du délai normal visé à la règle 107(1)(d) CBE, un montant correspondant à sept fois la taxe de désignation. Si une déclaration a été faite au n° 10.2, les taxes de désignation ne sont à prélever que pour les Etats contractants qui y sont indiqués, sauf instruction contraire reçue par l'OEB avant l'expiration du délai normal.</p>

<sup>1</sup> Stand bei Drucklegung: 27 Vertragsstaaten, und zwar: / Status when this form was printed: 27 contracting states, namely / Situation à la date d'impression : 27 Etats contractants, à savoir : AT Österreich / Austria / Autriche, BE Belgien / Belgium / Belgique, BG Bulgarien / Bulgaria / Bulgarie, CH / LI Schweiz und Liechtenstein / Switzerland and Liechtenstein / Suisse et Liechtenstein, CY Zypern / Cyprus / Chypre, CZ Tschechische Republik / Czech Republic / République tchèque, DE Deutschland / Germany / Allemagne, DK Dänemark / Denmark / Danemark, EE Estland / Estonia / Estonie, ES Spanien / Spain / Espagne, FI Finnland / Finland / Finlande, FR Frankreich / France / France, GB Vereinigtes Königreich / United Kingdom / Royaume-Uni, GR Griechenland / Greece / Grèce, HU Ungarn / Hungary / Hongrie, IE Irland / Ireland / Irlande, IT Italien / Italy / Italie, LU Luxemburg / Luxembourg / Luxembourg, MC Monaco / Monaco / Monaco, NL Niederlande / Netherlands / Pays-Bas, PT Portugal / Portugal / Portugal, RO Rumänien / Romania / Roumanie, SE Schweden / Sweden / Suède, SI Slowenien / Slovenia / Slovénie, SK Slowakische Republik / Slovak Republic / République slovaque, TR Türkei / Turkey / Turquie

<sup>2</sup> Für folgende Staaten nur möglich, falls in der internationalen Anmeldung am oder nach folgendem Tag bestimmt: Slowakische Republik, Bulgarien, Tschechische Republik und Estland: 1. Juli 2002, Slowenien: 1. Dezember 2002, Ungarn: 1. Januar 2003 und Rumänien: 1. März 2003. / For the following states this is possible only if they are designated in the international application on or after the stated date: Slovak Republic, Bulgaria, Czech Republic and Estonia: 1 July 2002, Slovenia: 1 December 2002, Hungary: 1 January 2003 and Romania: 1 March 2003. / En ce qui concerne les Etats suivants seulement si la désignation a été effectuée dans la demande internationale à la date suivante ou à une date ultérieure: République slovaque, Bulgarie, République tchèque et Estonie: 1<sup>er</sup> juillet 2002, Slovénie: 1<sup>er</sup> décembre 2002, Hongrie: 1<sup>er</sup> janvier 2003 et Roumanie: 1<sup>er</sup> mars 2003.

<input checked="" type="checkbox"/> <b>11. Erstreckung des europäischen Patents</b> Bei Zahlung der Erstreckungsgebühren gilt diese Anmeldung auch als wirksamer Erstreckungsantrag für die in der internationalen Anmeldung bestimmten »Erstreckungsstaaten«. Es ist beabsichtigt, diese Gebühren für folgende Staaten zu entrichten:  <input type="checkbox"/> SI Slowenien <sup>1)</sup> <input type="checkbox"/> LT Litauen <input type="checkbox"/> LV Lettland <input type="checkbox"/> AL Albanien <input type="checkbox"/> RO Rumänien <sup>1)</sup> <input type="checkbox"/> MK Ehemalige jugoslawische Republik Mazedonien <input type="checkbox"/> _____ <sup>2)</sup>	<b>11. Extension of the European patent</b>  On payment of the extension fee(s) this application is also deemed to be a request for extension to all the "extension states" designated in the international application. It is intended to pay the fee(s) for the following states:  Slovenia <sup>1)</sup> Lithuania Latvia Albania Romania <sup>1)</sup> Former Yugoslav Republic of Macedonia _____ <sup>2)</sup>	<b>11. Extension des effets du brevet européen</b> La taxe (Les taxes) d'extension payée(s), la présente demande est également réputée être une demande d'extension à tous les »Etats autorisant l'extension« désignés dans la demande internationale. Il est envisagé de payer la taxe (les taxes) d'extension pour les Etats suivants:  Slovénie <sup>1)</sup> Lituanie Lettonie Albanie Roumanie <sup>1)</sup> Ex-République yougoslave de Macédoine _____ <sup>2)</sup>
<p>1) Für Slowenien und Rumänien nur möglich, falls in der internationalen Anmeldung bis 30. November 2002 (Slowenien) oder bis 28. Februar 2003 (Rumänien) bestimmt. / For Slovenia and Romania this is possible only if they are designated in the international application up to 30 November 2002 (Slovenia) or 28 February 2003 (Romania). / En ce qui concerne la Slovénie et la Roumanie, seulement si la désignation a été effectuée dans la demande internationale jusqu'au 30 novembre 2002 (Slovénie) ou jusqu'au 28 février 2003 (Roumanie).</p> <p>2) Platz für Staaten, mit denen »Erstreckungsabkommen« nach Drucklegung dieses Formblatts in Kraft treten und die in der internationalen Anmeldung bestimmt waren. / Space for States with which "extension agreements" enter into force after this form has been printed and which were designated in the international application. / Prévu pour des Etats à l'égard desquels des »accords d'extension« entreraient en vigueur après l'impression du présent formulaire et qui ont été désignés dans la demande internationale.</p>		
<b>12. Automatischer Abbuchungsauftrag (Nur möglich für Inhaber von beim EPA geführten laufenden Konten)</b>  <input type="checkbox"/> Das EPA wird beauftragt, nach Maßgabe der Vorschriften über das automatische Abbuchungsverfahren fällige Gebühren und Auslagen vom untenstehenden laufenden Konto abzubuchen. In Bezug auf die <b>Benennungsgebühren</b> wird auf Feld 10.3 verwiesen. Das EPA wird ferner beauftragt, die <b>Erstreckungsgebühren</b> für jeden in Feld 11 angekreuzten »Erstreckungsstaat« bei Ablauf der Grundfrist zu ihrer Zahlung abzubuchen, sofern ihm nicht bis dahin ein anderslautender Auftrag zugeht.  Nummer und Kontoinhaber	<b>12. Automatic debit order (for EPO deposit account holders only)</b>  The EPO is hereby authorised, under the Arrangements for the automatic debiting procedure, to debit from the deposit account below any fees and costs falling due. For <b>designation fees</b> , see Section 10.3. The EPO is also authorised, on expiry of the basic period for paying the <b>extension fees</b> , to debit those fees for each of the "extension states" marked with a cross in Section 11, unless instructed otherwise before the said period expires.  Number and account holder	<b>12. Ordre de prélèvement automatique (uniquement possible pour les titulaires de comptes courants ouverts auprès de l'OEB)</b> Par la présente, il est demandé à l'OEB de prélever du compte courant ci-dessous les taxes et frais venant à échéance, conformément à la réglementation relative au prélèvement automatique. Pour les <b>taxes de désignation</b> , se reporter à la rubrique 10.3. Il est en outre demandé à l'OEB de prélever, à l'expiration du délai normal prévu pour leur paiement, les <b>taxes d'extension</b> pour chaque »Etat autorisant l'extension« coché à la rubrique 11, sauf instruction contraire reçue avant l'expiration de ce délai.  Numéro et titulaire du compte
<input checked="" type="checkbox"/> <b>13. Eventuelle Rückzahlungen auf das beim EPA geführte laufende Konto</b>  Nummer und Kontoinhaber	<b>13. Any reimbursement to EPO deposit account</b> Gill Jennings & Every LLP Number and account holder  2805.0014	<b>13. Remboursements éventuels à effectuer sur le compte courant ouvert auprès de l'OEB</b> Numéro et titulaire du compte
<b>14. Unterschrift(en) des (der) Anmelders(s) oder Vertreters</b>  Ort / Datum  Für Angestellte (Art. 133(3) EPÜ) mit allgemeiner Vollmacht:  Nr.  Name(n) des (der) Unterzeichneten bitte in Druckschrift wiederholen. Bei juristischen Personen bitte auch die Stellung des (der) Unterzeichneten innerhalb der Gesellschaft in Druckschrift angeben.	<b>14. Signature(s) of applicant(s) or representative</b>  SAMUELS, Lucy Alice Place / Date London/7 August 2006 For employees (Art. 133(3) EPC) having a general authorisation: No. Please print name(s) under signature(s). In the case of legal persons, the position of the signatory within the company should also be printed.	<b>14. Signature(s) du (des) demandeur(s) ou du mandataire</b>  Lieu / Date  Pour les employés (art. 133(3) CBE) disposant d'un pouvoir général: N° Le ou les noms des signataires doivent être indiqués en caractères d'imprimerie. S'il s'agit d'une personne morale, la position occupée au sein de celle-ci par le ou les signataires doit également être indiquée en caractères d'imprimerie.

## SEQUENCE LISTING

<110> GeneSense Technologies Inc. et al.

<120> Antisense Oligonucleotides Directed To  
Ribonucleotide Reductase R2 and Uses Thereof in Combination  
Therapies for the Treatment of Cancer

<130> 683-134pct

<140> n/a

<141> 2005-01-12

<150> US60/535,496

<151> 2004-01-12

<150> US60/602,817

<151> 2004-08-18

<160> 105

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense oligonucleotide complementary to human  
ribonucleotide reductase R2 mRNA

<400> 1  
ggctaaatcg ctccaccaag 20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Control antisense oligonucleotide

<400> 2  
ggctaaactc gtccaccaag 20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence



<220>  
<223> Control oligonucleotide

<400> 3  
acgcactcag ctagtgacac

20

<210> 4  
<211> 20  
<212> DNA  
<213> Artificial Sequence .

<220>  
<223> AS-II-6-20 antisense oligonucleotide complementary  
to human ribonucleotide reductase R2 mRNA

<400> 4  
acccttccca ttggctgcgc

20

<210> 5  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-13-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 5  
gcctccgacc cttcccattg

20

<210> 6  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-14-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 6  
tgctccgac ccttcccatt

20

<210> 7  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-16-18 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 7  
tgcctccgac ccttccca 18

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Partially Phosphorothioated AS-II-75-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 8  
cgcgcgctcc cggcccttcc 20

<210> 9  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-75-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 9  
cgcgcgctcc cggcccttcc 20

<210> 10  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-79-14 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 10  
cgcgctcccg gcc 14

<210> 11  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-109-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 11  
cccctcactc cagcagcctt

20

<210> 12  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-110-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 12  
acccttcact ccagcagcct

20

<210> 13  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-114-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 13  
ggcgaccct cactccagca

20

<210> 14  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-127-12 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 14  
gcacgggcga cc

12

<210> 15  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-130-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 15  
tgggacaggg tgcacgggcg

20

<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-134-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 16  
gacggctggg acaggggtgca

20

<210> 17  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-151-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 17  
gagcagccag gacaggacgg

20

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-163-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 18  
gcgaaagcaga gcgagcagcc

20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-166-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 19  
gcagcgaagc agagcgagca 20

<210> 20  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-185-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 20  
gggagagcat agtggaggcg 20

<210> 21  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-189-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 21  
cggagggaga gcatagtgga 20

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-201-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 22  
gcgagcggga cacggaggga 20

<210> 23  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-217-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 23  
cggggtccgtg atggg'gcgcga

20

<210> 24  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-225-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 24  
agctgctgcg ggtcogtgat

20

<210> 25  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-253-14 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 25  
ccccttcagc ggcg

14

<210> 26  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-280-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 26  
cggcggcgtg ttctccttgt

20

<210> 27  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-288-12 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 27  
cggcggcgtg tt

12

<210> 28  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-323-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 28  
tcctcgcggt cttgctggcc

20

<210> 29  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-344-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 29  
ccgtgggctc ctggaagatc

20

<210> 30  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-362-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 30  
ctgctttagt ttccggtcc

20

<210> 31  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-391-17 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 31  
cggctcatcc tccacgc

17

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-404-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 32  
ggttttctct cagcagcggc

20

<210> 33  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-412-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 33  
gcggcggggg ttttctctca

20

<210> 34  
<211> 20  
<212> DNA  
<213> Artificial Sequence

= <220>  
<223> AS-II-414-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 34  
aagcggcggg ggttttctct

20

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-425-20 antisense oligonucleotides



complementary to human ribonucleotide reductase R2  
mRNA

<400> 35  
ggaagatgac aaagcggcgg

20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-439-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 36  
atgggtactcg atggggaaga

20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-472-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 37  
agcctctgcc ttcttataca

20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-494-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 38  
cctcctcggc ggtccaaaag

20

<210> 39  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-496-16 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 39  
tcctcggcgg tccaaa 16

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-549-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 40  
tatctctcct cgggtttcag 20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-579-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 41  
gcaaagaaag ccagaacatg 20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-619-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 42  
tcgctccacc aagttttcat 20

<210> 43  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-634-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 43  
aacttcttgg ctaaatcgct

20

<210> 44  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-667-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 44  
gaagccatag aaacagcggg

20

<210> 45  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-784-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 45  
gacacaaggc atcgtttcaa

20

<210> 46  
<211> 20  
<212> DNA  
<213> Artificial Sequence

=<220>  
<223> AS-II-798-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 46  
tctgccttct tcttgacaca

20

<210> 47  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-816-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 47  
atccagcgca aggccagtc 20

<210> 48  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-861-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 48  
gcaaaggcta caacacgttc 20

<210> 49  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-890-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 49  
aaccggaaaa gaaaatgcct 20

<210> 50  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-909-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 50  
ggcatcagtc ctcgtttcct 20

<210> 51  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-933-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 51  
ggcatcagtc ctcgtttctt 20

<210> 52  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-981-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 52  
tgtaaaccct catctctgt 20

<210> 53  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1001-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 53  
tcaggcaagc aaaatcacag 20

<210> 54  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1006-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 54  
gaacatcagg caagcaaat 20

<210> 55  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1023-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 55  
ttgtgtacca ggtgtttgaa 20

<210> 56  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1040-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 56  
ctctctcctc cgatggtttg 20

<210> 57  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1048-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 57  
ttctcttact ctctcctccg 20

<210> 58  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1144-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 58  
gtattgcttc attagagtgc 20

<210> 59  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1182-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 59  
cccagttcca gcataagtct 20

<210> 60  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1197-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 60  
aaaaccttgc taaaaccag 20

<210> 61  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1217-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 61  
caaatgggtt ctctactctg 20

<210> 62  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1224-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 62  
ataaagtcaa atgggttctc 20

<210> 63  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1254-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 63  
ttagtcctttc cttccagtga 20

<210> 64  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1278-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 64  
tcgcctactc tcttctcaaa 20

<210> 65  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1288-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 65  
cctctgatac tcgcctactc 20

<210> 66  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1302-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 66  
gacatcactc ccacctctg 20

<210> 67  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1335-20 antisense oligonucleotides



complementary to human ribonucleotide reductase R2  
mRNA

<400> 67  
gcatccaagg taaaagaatt

20

<210> 68  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1338-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 68  
tcagcatcca aggtaaaaga

20

<210> 69  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1342-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 69  
gaagtcagca tccaaggtaa

20

<210> 70  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1345-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 70  
ttagaagtca gcatccaagg

20

<210> 71  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1362-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 71  
gcacatcttc agttcattta

20

<210> 72  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1364-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 72  
gggcacatct tcagttcatt

20

<210> 73  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1381-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 73  
aaaaatcagc caagtaaggg

20

<210> 74  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1390-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 74  
atggaaaaaa aaaatcagcc

20

<210> 75  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1438-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 75  
ttcatgggtgt ggctagttgg

20

<210> 76  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1499-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 76  
aggactgggtt gtgaggtagc

20

<210> 77  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1517-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 77  
ccagcactat aaacagacag

20

<210> 78  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1538-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 78  
ttctggcaaa aggtgatact

20

<210> 79  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1560-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 79  
gtaagtcaca gccagccagg 20

<210> 80  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1581-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 80  
actgccattg tcaactgctat 20

<210> 81  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1659-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 81  
tggctgtgct gggttaaagga 20

<210> 82  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
= <223> AS-II-1666-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 82  
ttttaactgg ctgtgctggt 20

<210> 83  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1700-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 83  
attaaaaatct gcggtgaagc

20

<210> 84  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1768-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 84  
tatcgccgcc gtgagtacaa

20

<210> 85  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1773-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 85  
gctattatcg ccgccgtgag

20

<210> 86  
<211> 12  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1775-12 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 86  
atcgccgccg tg

12

<210> 87  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1790-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 87  
gaaaccaa ataatcaagct 20

<210> 88  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1819-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 88  
ttagtggtca ggagaatgta 20

<210> 89  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1976-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 89  
tggcaccaac tgactaatat 20

<210> 90  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-1989-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 90  
cctgtcttct atctggcacc 20

<210> 91  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2009-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 91  
gccacaggat aaaaacacaa

20

<210> 92  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2026-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 92  
cccaggacac tacacaagcc

20

<210> 93  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2044-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 93  
tcagaggggg cagagaatcc

20

<210> 94  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2067-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 94  
tcctttatcc cacaacactc

20

<210> 95  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2083-20 antisense oligonucleotides

complementary to human ribonucleotide reductase R2  
mRNA

<400> 95  
ccttgccctg agagattcct

20

<210> 96  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Partially Phosphorothioated AS-II-2083-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 96  
ccttgccctg agagattcct

20

<210> 97  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2128-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 97  
ggcccagatc acccctaaat

20

<210> 98  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2151-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 98  
aaacggcttc tcacacatat

20

<210> 99  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2164-20 antisense oligonucleotides



complementary to human ribonucleotide reductase R2  
mRNA

<400> 99  
gagaaataaa atgaaacggc

20

<210> 100  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2182-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 100  
cgttgaggaa aatacagtga

20

<210> 101  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2229A-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 101  
gctcccat atgaaaactc

20

<210> 102  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> AS-II-2372-20 antisense oligonucleotides  
complementary to human ribonucleotide reductase R2  
mRNA

<400> 102  
cacacaacct acttacacca

20

<210> 103  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense oligonucleotides complementary to human

## ribonucleotide reductase R2 mRNA

<400> 103  
tcctggaaga tctcctcgc

20

<210> 104  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Antisense oligonucleotides complementary to human  
ribonucleotide reductase R2 mRNA

<400> 104  
tcccacatat gagaaaaactc

20

<210> 105  
<211> 2500  
<212> DNA  
<213> Homo sapiens

<220>  
<221> mRNA  
<222> (1)... (2500)  
<223> ribonucleotide reductase R2 mRNA

<400> 105  
cccaggcgca gccaatggga agggctcggag gcatggcaca gccaatggga agggccgggg 60  
oaccaaagcc aatgggaagg gccgggagcg cgcggcgcgg gagatttaaa ggctgctgga 120  
gtgaggggto gccogtgcac cctgtcccag ccgtcctgtc ctggctgctc gctctgcttc 180  
gctgcgcctc cactatgctc tccctccgtg tcccgctcgc gccatcacg gacccgcagc 240  
agctgcagct ctgcgcgctg aaggggctca gcttggctga caaggagaac acgcccggcg 300  
ccctgagcgg gacccgcgct ctggccagca agaccgcgag gaggatcttc caggagccca 360  
cggagccgaa aactaaagca gctgcccccg gcgtggagga tgagccgctg ctgagagaaa 420  
accccgccg cttgtcctc tccccatcg agtaccatga tatctggcag atgtataaga 480  
aggcagaggg ttccttttgg accgcccagg aggttgacct ctccaaggac attcagcact 540  
gggaatccct gaaacccgag gagagatatt ttatatccca tgttctggot tcttttgca 600  
caagcgatgg catagtaaat gaaaacttgg tggagcgatt tagccaagaa gttagatta 660  
cagaagcccc ctgtttctat ggcttccaaa ttgccatgga aaacatacat tctgaaatgt 720  
atagtcttct tattgacact tacataaaaag atcccaaaga aagggaattt ctcttcaatg 780  
ccattgaaac gatgccttgt gtcaagaaga aggcagactg ggccttgccg tggattgggg 840  
acaaagaggg tacctatggt gaacgtgttg tagcctttgc tgcagtggaa ggcattttct 900  
tttccggttc ttttgcgtcg atattctggc tcaagaaaac aggactgatg cctggootca 960  
cattttctaa tgaacttatt agcagagatg agggtttaca ctgtgatttt gcttgccctga 1020  
tgttcaaca cctggtacac aaaccatcgg aggagagagt aagagaaata attatcaatg 1080  
ctgttcggat agaacaggag ttcctcactg aggccttgcc tgtgaagctc attgggatga 1140  
attgactct aatgaagcaa tacattgagt ttgtggcaga cagacttatg ctggaaactgg 1200  
gttttagcaa ggttttcaga gtagagaacc catttgactt tatggagaat atttcactgg 1260  
aaggaaagac taacttcttt gagaagagag taggcgagta tcagaggatg ggagtgatgt 1320  
caagtccaac agagaattct ttaccttgg atgctgactt ctaaatgaac tgaagatgtg 1380  
cccttacttg gctgatTTTT ttttcccatc tcataagaaa aatcagctga agtgttacca 1440

```
actagccaca ccatgaattg tccgtaatgt tcattaacag catcttttaa actgtgtagc 1500
tacctcacia ccagtcctgt ctgtttatag tgctggtagt atcacctttt gccagaaggg 1560
ctggctggct gtgacttacc atagcagtga caatggcagt cttggcttta aagtgagggg 1620
tgaccottha gtgagcttag cacagcggga ttaaacagtc ctttaaccag cacagccagt 1680
taaaagatgc agcctcactg cttcaacgca gattttaatg tttacttaa tataaacctg 1740
gcactttaca aacaaataaa cattgttttg tactcacggc ggcgataata gcttgattta 1800
tttggtttct acaccaaata catttcctg accactaatg ggagccaatt cacaattcac 1860
taagtgaacta aagtaagtta aacttgtgta gactaagcat gtaattttta agttttattt 1920
taatgaatta aaatatattgt taaccaactt taaagtcagt cctgtgtata cctagatatt 1980
agtcagttgg tgccagatag aagacaggtt gtgtttttat cctgtggctt gtgtagtgtc 2040
ctgggattct ctgccccctc tgagtagagt gttgtgggat aaaggaatct ctcagggcaa 2100
ggagcttctt aagttaaatc actagaaatt taggggtgat ctgggccttc atatgtgtga 2160
gaagccgttt cattttattt ctcactgtat ttccctcaac gtctgggtga tgagaaaaaa 2220
ttcttgaaga gttttcatat gtgggagcta aggtagtatt gtaaaatttc aagtcaccc 2280
taaacaaaat gatccaccta agatcttgcc cctgttaagt ggtgaaatca actagagggt 2340
gttcctacaa gttgttcatt ctagttttgt ttggtgtaag taggttgtgt gagttaattc 2400
atztatattt actatgtctg ttaaatcaga aattttttat tatctatgtt cttctagatt 2460
ttacctgtag ttcataaaaa aaaaaaaaaa aaaaaaaaaa 2500
```

**THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:**

1. A combination product for use in the treatment of cancer in a mammal, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA and one or more immunotherapeutic agents.
2. The combination product according to claim 1, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.
3. The combination product according to claim 2, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.
4. The combination product according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.
5. The combination product according to claim 2, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.
6. The combination product according to any one of claims 1 to 5, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.
7. The combination product according to any one of claims 1 to 6, wherein said cancer is an advanced cancer.
8. The combination product according to any one of claims 1 to 7, wherein said cancer is a metastatic cancer.
9. The combination product according to any one of claims 1 to 8, wherein said treatment is a first-line systemic therapy.

10. The combination product according to any one of claims 1 to 9, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.
11. The combination product according to any one of claims 1 to 9, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.
12. The combination product according to any one of claims 1 to 10, wherein said one or more immunotherapeutic agents are selected from the group of: a cytokine, a non-cytokine adjuvant, a monoclonal antibody and a cancer vaccine.
13. The combination product according to any one of claims 1 to 10, wherein said one or more immunotherapeutic agents are selected from the group of: a cytokine and a non-cytokine adjuvant.
14. The combination product according to any one of claims 1 to 10, wherein said one or more immunotherapeutic agents are one or more cytokines.
15. The combination product according to any one of claims 1 to 14, wherein said combination product further comprises one or more chemotherapeutic agents.
16. The combination product according to any one of claims 1 to 15, wherein said cancer is a solid cancer.
17. The combination product according to any one of claims 1 to 16, wherein said mammal is a human.
- ~~18. A method of treating cancer in a mammal comprising administering to said mammal a combination product comprising:
  - (a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and
  - (b) one or more immunotherapeutic agents.~~
19. The method according to claim 18, wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.

20. The combination product according to claim 19, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.
21. The method according to claim 19, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.
22. The method according to according to claim 19, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.
23. The method according to any one of claims 18 to 22, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.
24. The method according to any one of claims 18 to 23, wherein said cancer is an advanced cancer.
25. The method according to any one of claims 18 to 24, wherein said cancer is a metastatic cancer.
26. The method according to any one of claims 18 to 25, wherein said combination product is administered to said mammal as first-line systemic therapy.
27. The method according to any one of claims 18 to 26, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.
28. The method according to any one of claims 18 to 26, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.
29. The method according to any one of claims 18 to 27, wherein said one or more immunotherapeutic agents are selected from the group of: a cytokine, a non-cytokine adjuvant, a monoclonal antibody and a cancer vaccine.
30. The method according to any one of claims 18 to 27, wherein said one or more immunotherapeutic agents are selected from the group of: a cytokine and a non-cytokine adjuvant.

- ~~31. The method according to any one of claims 18 to 27, wherein said one or more immunotherapeutic agents are one or more cytokines.~~
32. The method according to any one of claims 18 to 31, wherein said combination product further comprises one or more chemotherapeutic agents.
33. The method according to any one of claims 18 to 32, wherein said cancer is a solid cancer.
34. The method according to any one of claims 18 to 33, wherein said mammal is a human.
- 18 ~~25.~~ Use of an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA and one or more immunotherapeutic agents in the manufacture of a medicament for the treatment of cancer in a mammal.
- 19 ~~26.~~ The use according to claim <sup>18</sup> ~~25~~, <sup>additionally comprising any of the features of claims 2 to 17.</sup> wherein said mammalian ribonucleotide reductase R2 subunit mRNA is a human ribonucleotide reductase R2 subunit mRNA.
37. The use according to claim 36, wherein said human ribonucleotide reductase R2 subunit mRNA has a sequence as set forth in SEQ ID NO:105.
38. The use according to claim 36, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in any one of SEQ ID NOs:1 and 4-104.
39. The use according to claim 36, wherein said antisense oligonucleotide comprises at least 7 consecutive nucleotides of the sequence as set forth in SEQ ID NO:1.
40. The use according to any one of claims 35 to 39, wherein said antisense oligonucleotide comprises one or more phosphorothioate internucleotide linkages.
41. The use according to any one of claims 35 to 40, wherein said cancer is an advanced cancer.

~~42. The use according to any one of claims 35 to 41, wherein said cancer is a metastatic cancer.~~

43. The use according to any one of claims 35 to 42, wherein said treatment is a first-line systemic therapy.

44. The use according to any one of claims 35 to 43, wherein said one or more immunotherapeutic agents are non-specific immunotherapeutic agents.

45. The use according to any one of claims 35 to 43, wherein said one or more immunotherapeutic agents are specific immunotherapeutic agents.

46. The use according to any one of claims 35 to 44, wherein said one or more immunotherapeutic agents are selected from the group of: a cytokine, a non-cytokine adjuvant, a monoclonal antibody and a cancer vaccine.

47. The use according to any one of claims 35 to 44, wherein said one or more immunotherapeutic agents are selected from the group of: a cytokine and a non-cytokine adjuvant.

48. The use according to any one of claims 35 to 44, wherein said one or more immunotherapeutic agents are one or more cytokines.

49. The use according to any one of claims 35 to 48, wherein said combination product further comprises one or more chemotherapeutic agents.

50. The use according to any one of claims 35 to 49, wherein said cancer is a solid cancer.

51. The use according to any one of claims 35 to 50, wherein said mammal is a human

20 52. A pharmaceutical kit comprising a combination product for the treatment of cancer, said combination product comprising:

- (a) an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to a mammalian ribonucleotide reductase R2 subunit mRNA, and



(b) one or more immunotherapeutic agents:

21. 53. A combination product for use in the treatment of renal cancer in a subject, said combination product comprising: an antisense oligonucleotide of between 7 and 100 nucleotides in length comprising at least 7 consecutive nucleotides complementary to SEQ ID NO:1 and one or more cytokines.

22. 54. The combination product according to claim <sup>21</sup>53, wherein said one or more cytokines are selected from: interferon alpha and interleukin-2.

23. 55. The combination product according to claim <sup>21</sup>53 or <sup>22</sup>54, wherein said treatment is a first-line systemic therapy.